Search

for
Search:

GlossaryRU58841 (PSK-3841)

non-steroidal anti-androgen researched for treating androgenic alopecia

RU58841 is a non-steroidal anti-androgen that is often researched for its potential to treat androgenic alopecia (pattern hair loss). It works by binding to androgen receptors in the scalp, thereby preventing dihydrotestosterone (DHT) from attaching to these receptors and causing hair follicle miniaturization.

Related Terms

Products matching "psk-3841"

Tracking 1 products like 265 RU-58841 Solution 50mg/ml – 50ml from by companies like Chemyo. View product »

Sort by

Community Join

8 / 8 results

community The story of RU58841 / PSK 3841

in Research/Science 22 upvotes 3 months ago

RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. RU58841 is highlighted for its potential effectiveness.

community I spoke to the Guy who did the Ru58841 (PSK-3841) research

in Research/Science 288 upvotes 3 years ago

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

community Research about RU58841 /Why it was stopped

in Research/Science 29 upvotes 3 years ago

RU58841 showed promise for treating androgenic alopecia but research was halted due to financial and organizational changes. There were no significant safety concerns reported in human trials.

community For all those worried about a minoxidil break

in Minoxidil 342 upvotes 3 months ago

Stopping minoxidil can lead to significant hair loss, but resuming it along with finasteride can help regain lost hair over time. Consistency is key for maintaining hair health and regrowth.

community The story of RU58841/ PSK3841

in Research 622 upvotes 3 months ago

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

community Safety of RU-58841: I talked to the Pharma Company that researched it, Human Clinical Trials, and Potential Reasons for Discontinuation

in Research/Science 142 upvotes 1 year ago

The safety and effectiveness of RU-58841 as a hair loss treatment, with some users reporting side effects like chest pains, while others had positive results. The original research on RU-58841 was likely stopped due to financial issues, not safety concerns.

community ~5 months topical minoxidil + oral finasteride results (swipe images). Slacked with minoxidil this past month, trying to wean off anyways. My last update because I’m hopping off fin and switching to RU in a few weeks (nothing to do with fin efficacy, just experimenting).

in Progress Pictures 145 upvotes 4 years ago

The user experienced significant hair thickening after using topical minoxidil and oral finasteride for about 5 months and is considering switching from finasteride to RU58841. Other users encourage the original poster to continue the current treatment due to the positive results.

community The story of RU58841/PSK3841

in Research/Science 3 months ago

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.